Drug Profile
Farletuzumab radioimmunotherapy - Eisai Inc/University of Gothenburg
Latest Information Update: 28 Dec 2019
Price :
$50
*
At a glance
- Originator Morphotek; University of Gothenburg
- Class Drug conjugates; Monoclonal antibodies; Radiopharmaceuticals
- Mechanism of Action Ionising radiation emitters
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Ovarian cancer
Most Recent Events
- 28 Dec 2019 No recent reports of development identified for research development in Ovarian-cancer in Unknown (Parenteral)
- 17 Nov 2015 Morphotek and the University of Gothenburg agree to co-develop farletuzumab radioimmunotherapy for Ovarian cancer
- 17 Nov 2015 Early research in Ovarian cancer (Parenteral)